Rhonda M Cooper-DeHoff, Pharm.D., M.S., FAHA, FACC, FCCP
Associate Professor
Department:
Pharmacotherapy & Translational Research
Business Phone:
(352) 359-2658
Business Email:
rmdehoff@ufl.edu
About Rhonda M Cooper-DeHoff
Dr. Cooper-DeHoff is a Associate Professor in the Department of Pharmacotherapy and Translational Research, and the Department of Pharmaceutics in the College of Pharmacy, and in the Division of Cardiovascular Medicine, College of Medicine at the University of Florida.
Accomplishments
Fellow
2014
·
American College of Clinical Pharmacy
Research Featured
2009
·
American Society of Hypertension
Clinical Science Award
2008
·
Consortium for Southeastern Hypertension Control
Fellow
2007
·
American Heart Association
Teaching Profile
Courses Taught
2016-2018,2020-2021
PHA5878C Pt Care 3: Cv and Pulm
2016,2020-2021
PHA6910 Supervised Research
2013-2022
PHA7980 Research for Doctoral Dissertation
2013-2021
PHA7979 Advanced Research
2019-2021
PHA6613 Clinical Applications Precision Medicine: Precision Health
2017-2018
PHA5012 App Personalized Med
2014-2018,2021-2022
PHA6938 Research Seminar
2016-2017,2021
PHA6971 Research for Master’s Thesis
2010-2011,2016
PHA6935 Selected Topics in Pharmacy
2011-2015
PHA5782 Pharmacotherapy 2
2011,2013-2014
PHA5907 Research in Phar Prac
2012-2014
PHA6892 Practices and Procedures of the IRB
2011,2013
PHA6633 Mtm: Cardiovascular
2013
PHA4914 Undergraduate Research in Pharmacotherapy and Translational Research
Research Profile
Dr. Cooper-DeHoff’s research interests include hypertension, metabolic syndrome, diabetes, coronary artery disease and antihypertensive drug-induced diabetes, as well as the impact of pharmacogenetic variations in each of these areas. She’s also the lead investigator of the hypertension working group within the Patient-Centered Outcomes Research Institute-funded Clinical Data Research Network — OneFlorida — which affords trainees the opportunity to work at an epidemiologic level to explore population-level questions about hypertension. Trainees also learn about the complexities and benefits of working in electronic health record data at the research level. Dr. Cooper-DeHoff’s resistant hypertension research includes mass spectrometry analysis of antihypertensive drugs, metabolomics and gut microbiota available for analysis.
Open Researcher and Contributor ID (ORCID)
0000-0002-5198-130X
Publications
2024
Characteristics and Predictors of Apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
American journal of hypertension.
37(1):60-68
[DOI] 10.1093/ajh/hpad084.
[PMID] 37712350.
2024
Circulating microRNA Biomarkers of Thiazide Response in Hypertension
Journal of the American Heart Association.
13(4)
[DOI] 10.1161/jaha.123.032433.
2024
Implementation of a pharmacogenetic panel‐based test for pharmacotherapy‐based supportive care in an adult oncology clinic
Clinical and Translational Science.
17(7)
[DOI] 10.1111/cts.13890.
[PMID] 39046302.
2024
Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
Hypertension.
81(2)
[DOI] 10.1161/hypertensionaha.123.21901.
2024
Integrated metabolomics analysis reveals mechanistic insights into variability in blood pressure response to thiazide diuretics and beta blockers
Clinical and Translational Science.
17(5)
[DOI] 10.1111/cts.13816.
[PMID] 38747311.
2024
Use of Electronic Health Records to Characterize Patients with Uncontrolled Hypertension in Two Large Health System Networks.
Research square.
[DOI] 10.21203/rs.3.rs-3943912/v1.
[PMID] 38410433.
2023
Characteristics and Predictors of Apparent Treatment Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2023.04.28.23289293.
[PMID] 37205447.
2023
Disruption in Blood Pressure Control With the COVID-19 Pandemic: The PCORnet Blood Pressure Control Laboratory.
Mayo Clinic proceedings.
98(5):662-675
[DOI] 10.1016/j.mayocp.2022.12.024.
[PMID] 37137641.
2023
Improvement in Blood Pressure Control in Safety Net Clinics Receiving 2 Versions of a Scalable Quality Improvement Intervention: BP MAP A Pragmatic Cluster Randomized Trial
Journal of the American Heart Association.
12(3)
[DOI] 10.1161/jaha.121.024975.
2023
In Reply: Probability of Reduced Follow-up Health Care Visits for Controlled Hypertensive Patients.
Mayo Clinic proceedings.
98(6)
[DOI] 10.1016/j.mayocp.2023.04.005.
[PMID] 37270276.
2023
Initial Antihypertensive Regimens in Newly Treated Patients: Real World Evidence From the OneFlorida+ Clinical Research Network
Journal of the American Heart Association.
12(1)
[DOI] 10.1161/jaha.122.026652.
2023
Medication Adherence—Still the Holy Grail
Journal of the American Heart Association.
12(4)
[DOI] 10.1161/jaha.122.028688.
2023
New Drugs Approved in 2022.
The American journal of medicine.
136(6):545-550
[DOI] 10.1016/j.amjmed.2023.02.019.
[PMID] 36889492.
2023
Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale.
Journal of the American Geriatrics Society.
71(6):1701-1713
[DOI] 10.1111/jgs.18312.
[PMID] 37082807.
2023
Racial and Ethnic Differences in Cardiac Surveillance Evaluation of Patients Treated With Anthracycline‐Based Chemotherapy
Journal of the American Heart Association.
12(10)
[DOI] 10.1161/jaha.122.027981.
2023
Seasonal variation in blood pressure control across US health systems.
Journal of hypertension.
41(5):751-758
[DOI] 10.1097/HJH.0000000000003396.
[PMID] 36883471.
2023
Use of Electronic Health Records to Characterize Patients with Uncontrolled Hypertension in Two Large Health System Networks.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2023.07.26.23293225.
[PMID] 37546792.
2022
Acetaminophen-Induced Hypertension: Where Have All the “Safe” Analgesics Gone?
Circulation.
145(6):424-426
[DOI] 10.1161/circulationaha.121.058068.
2022
Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and COVID-19-related outcomes: A patient-level analysis of the PCORnet blood pressure control lab.
American heart journal plus : cardiology research and practice.
13
[DOI] 10.1016/j.ahjo.2022.100112.
[PMID] 35252907.
2022
Assessment of a Manual Method versus an Automated, Probability-Based Algorithm to Identify Patients at High Risk for Pharmacogenomic Adverse Drug Outcomes in a University-Based Health Insurance Program
Journal of Personalized Medicine.
12(2)
[DOI] 10.3390/jpm12020161.
[PMID] 35207649.
2022
Associations of Polymorphisms in the Peroxisome Proliferator-Activated Receptor Gamma Coactivator-1 Alpha Gene With Subsequent Coronary Heart Disease: An Individual-Level Meta-Analysis.
Frontiers in physiology.
13
[DOI] 10.3389/fphys.2022.909870.
[PMID] 35812313.
2022
Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension.
Contemporary clinical trials.
119
[DOI] 10.1016/j.cct.2022.106813.
[PMID] 35660539.
2022
Effectiveness of Standard vs Enhanced Self-measurement of Blood Pressure Paired With a Connected Smartphone Application: A Randomized Clinical Trial.
JAMA internal medicine.
182(10):1025-1034
[DOI] 10.1001/jamainternmed.2022.3355.
[PMID] 35969408.
2022
Genetic Contributors of Efficacy and Adverse Metabolic Effects of Chlorthalidone in African Americans from the Genetics of Hypertension Associated Treatments (GenHAT) Study
Genes.
13(7)
[DOI] 10.3390/genes13071260.
[PMID] 35886043.
2022
Influence of Genetic West African Ancestry on Metabolomics among Hypertensive Patients
Metabolites.
12(9)
[DOI] 10.3390/metabo12090783.
[PMID] 36144188.
2022
New Drugs Approved in 2021.
The American journal of medicine.
135(7):836-839
[DOI] 10.1016/j.amjmed.2022.01.055.
[PMID] 35235820.
2022
Pairwise comparison of hydrochlorothiazide and chlorthalidone responses among hypertensive patients.
Clinical and translational science.
15(12):2858-2867
[DOI] 10.1111/cts.13396.
[PMID] 36271676.
2022
Sex-dimorphic gene effects on survival outcomes in people with coronary artery disease.
American heart journal plus : cardiology research and practice.
17
[DOI] 10.1016/j.ahjo.2022.100152.
[PMID] 35959094.
2022
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.
Clinical pharmacology and therapeutics.
111(5):1007-1021
[DOI] 10.1002/cpt.2557.
[PMID] 35152405.
2021
Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.
Clinical pharmacology and therapeutics.
110(3):723-732
[DOI] 10.1002/cpt.2355.
[PMID] 34231218.
2021
Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans.
PloS one.
16(4)
[DOI] 10.1371/journal.pone.0248080.
[PMID] 33891615.
2021
Antihypertensive medication adherence trends by sex and drug class: A pilot study
American Heart Journal Plus: Cardiology Research and Practice.
5
[DOI] 10.1016/j.ahjo.2021.100023.
[PMID] 38560412.
2021
Association of 1-Year Blood Pressure Variability With Long-term Mortality Among Adults With Coronary Artery Disease: A Post Hoc Analysis of a Randomized Clinical Trial.
JAMA network open.
4(4)
[DOI] 10.1001/jamanetworkopen.2021.8418.
[PMID] 33914047.
2021
Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network.
Genetics in medicine : official journal of the American College of Medical Genetics.
23(7):1185-1191
[DOI] 10.1038/s41436-021-01118-9.
[PMID] 33782552.
2021
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality.
European heart journal.
42(18):1742-1756
[DOI] 10.1093/eurheartj/ehab107.
[PMID] 33748830.
2021
Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
Clinical and translational science.
14(2):492-496
[DOI] 10.1111/cts.12939.
[PMID] 33278335.
2021
Metabolomics Signature of Plasma Renin Activity and Linkage with Blood Pressure Response to Beta Blockers and Thiazide Diuretics in Hypertensive European American Patients.
Metabolites.
11(9)
[DOI] 10.3390/metabo11090645.
[PMID] 34564461.
2021
Multi-Institutional Implementation of Clinical Decision Support for APOL1, NAT2, and YEATS4 Genotyping in Antihypertensive Management.
Journal of personalized medicine.
11(6)
[DOI] 10.3390/jpm11060480.
[PMID] 34071920.
2021
New Drugs Approved in 2020.
The American journal of medicine.
134(9):1096-1100
[DOI] 10.1016/j.amjmed.2021.03.034.
[PMID] 33939997.
2021
Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.
Cardio-oncology (London, England).
7(1)
[DOI] 10.1186/s40959-021-00097-9.
[PMID] 33736707.
2021
Optimizing Precision of Hypertension Care to Maximize Blood Pressure Control: A Pilot Study Utilizing a Smartphone App to Incorporate Plasma Renin Activity Testing.
Clinical and translational science.
14(2):617-624
[DOI] 10.1111/cts.12922.
[PMID] 33142006.
2021
Potential of Minocycline for Treatment of Resistant Hypertension.
The American journal of cardiology.
156:147-149
[DOI] 10.1016/j.amjcard.2021.07.004.
[PMID] 34348841.
2021
Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.
The American journal of medicine.
134(7):918-925.e2
[DOI] 10.1016/j.amjmed.2020.12.015.
[PMID] 33434556.
2021
Rationale and design of the Women’s Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial.
American heart journal.
237:90-103
[DOI] 10.1016/j.ahj.2021.03.011.
[PMID] 33745898.
2021
Tracking Blood Pressure Control Performance and Process Metrics in 25 US Health Systems: The PCORnet Blood Pressure Control Laboratory
Journal of the American Heart Association.
10(21)
[DOI] 10.1161/jaha.121.022224.
2020
Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data.
Circulation.
142(6):546-555
[DOI] 10.1161/CIRCULATIONAHA.119.045526.
[PMID] 32654539.
2020
Attended vs unattended systolic blood pressure measurement: A randomized comparison in patients with cardiovascular disease
The Journal of Clinical Hypertension.
22(11):1987-1992
[DOI] 10.1111/jch.14037.
[PMID] 32951360.
2020
Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.
American journal of hypertension.
33(4):316-324
[DOI] 10.1093/ajh/hpz196.
[PMID] 31853537.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology.
9(12):678-685
[DOI] 10.1002/psp4.12563.
[PMID] 33067866.
2020
Genotype-Guided Hydralazine Therapy.
American journal of nephrology.
51(10):764-776
[DOI] 10.1159/000510433.
[PMID] 32927458.
2020
How to Transition from Single-Gene Pharmacogenetic Testing to Preemptive Panel-Based Testing: A Tutorial.
Clinical pharmacology and therapeutics.
108(3):557-565
[DOI] 10.1002/cpt.1912.
[PMID] 32460360.
2020
New Drugs Approved in 2019.
The American journal of medicine.
133(6):675-678
[DOI] 10.1016/j.amjmed.2020.01.030.
[PMID] 32145207.
2020
Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVEST☆.
International Journal of Cardiology. Hypertension.
7
[DOI] 10.1016/j.ijchy.2020.100052.
[PMID] 33817619.
2020
Optimizing Antihypertensive Medication Classification in Electronic Health Record-Based Data: Classification System Development and Methodological Comparison
JMIR Medical Informatics.
8(2)
[DOI] 10.2196/14777.
[PMID] 32130152.
2020
Optimizing identification of resistant hypertension: Computable phenotype development and validation.
Pharmacoepidemiology and drug safety.
29(11):1393-1401
[DOI] 10.1002/pds.5095.
[PMID] 32844549.
2020
Redefining Resistant Hypertension: A Comparison of Cardiovascular Risk Associated With the 2018 Versus 2008 American Heart Association Definitions for Resistant Hypertension.
Circulation. Cardiovascular quality and outcomes.
13(2)
[DOI] 10.1161/CIRCOUTCOMES.119.005979.
[PMID] 32008359.
2020
Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence.
American journal of hypertension.
33(2)
[DOI] 10.1093/ajh/hpz168.
[PMID] 31891170.
2020
Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST).
Journal of women's health (2002).
29(2):158-166
[DOI] 10.1089/jwh.2018.7235.
[PMID] 31403360.
2020
Sorting nexin 1 loss results in increased oxidative stress and hypertension.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
34(6):7941-7957
[DOI] 10.1096/fj.201902448R.
[PMID] 32293069.
2020
Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure.
ESC heart failure.
7(1):123-129
[DOI] 10.1002/ehf2.12534.
[PMID] 31840441.
2020
The PCORnet Blood Pressure Control Laboratory: A Platform for Surveillance and Efficient Trials.
Circulation. Cardiovascular quality and outcomes.
13(3)
[DOI] 10.1161/CIRCOUTCOMES.119.006115.
[PMID] 32142371.
2020
Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus: A Point of Clarification.
Hypertension (Dallas, Tex. : 1979).
75(3):e2-e5
[DOI] 10.1161/HYPERTENSIONAHA.119.14447.
[PMID] 32008437.
2019
Antihypertensive therapy prescribing patterns and correlates of blood pressure control among hypertensive patients with chronic kidney disease.
Journal of clinical hypertension (Greenwich, Conn.).
21(1):91-101
[DOI] 10.1111/jch.13429.
[PMID] 30427124.
2019
Atherosclerotic cardiovascular disease risk assessment and predictors of statin use in Filipino-American Women.
Journal of clinical pharmacy and therapeutics.
44(4):632-639
[DOI] 10.1111/jcpt.12837.
[PMID] 30963623.
2019
Effect of plasma MicroRNA on antihypertensive response to beta blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
131:93-98
[DOI] 10.1016/j.ejps.2019.02.013.
[PMID] 30753892.
2019
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.
The American journal of medicine.
132(2):172-174
[DOI] 10.1016/j.amjmed.2018.08.027.
[PMID] 30240679.
2019
Gene Variants at Loci Related to Blood Pressure Account for Variation in Response to Antihypertensive Drugs Between Black and White Individuals.
Hypertension (Dallas, Tex. : 1979).
74(3):614-622
[DOI] 10.1161/HYPERTENSIONAHA.118.12177.
[PMID] 31327267.
2019
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.
Scientific reports.
9(1)
[DOI] 10.1038/s41598-019-53345-5.
[PMID] 31754133.
2019
Genome-wide association analysis of common genetic variants of resistant hypertension.
The pharmacogenomics journal.
19(3):295-304
[DOI] 10.1038/s41397-018-0049-x.
[PMID] 30237584.
2019
Genome-Wide Meta-Analysis of Blood Pressure Response to β1-Blockers: Results From ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies).
Journal of the American Heart Association.
8(16)
[DOI] 10.1161/JAHA.119.013115.
[PMID] 31423876.
2019
Genomic Association Analysis Reveals Variants Associated With Blood Pressure Response to Beta-Blockers in European Americans.
Clinical and translational science.
12(5):497-504
[DOI] 10.1111/cts.12643.
[PMID] 31033190.
2019
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
PloS one.
14(9)
[DOI] 10.1371/journal.pone.0221957.
[PMID] 31532792.
2019
Incidence, prevalence, and predictors of treatment-resistant hypertension with intensive blood pressure lowering.
Journal of clinical hypertension (Greenwich, Conn.).
21(6):825-834
[DOI] 10.1111/jch.13550.
[PMID] 31066177.
2019
New Drug Approvals in 2018 – Another Record Year!
The American journal of medicine.
132(9):1038-1043
[DOI] 10.1016/j.amjmed.2019.02.024.
[PMID] 30853471.
2019
Objectively measured pediatric obesity prevalence using the OneFlorida Clinical Research Consortium.
Obesity research & clinical practice.
13(1):12-15
[DOI] 10.1016/j.orcp.2018.10.002.
[PMID] 30391132.
2019
PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network.
Journal of the American Heart Association.
8(9)
[DOI] 10.1161/JAHA.118.011246.
[PMID] 31020929.
2019
Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension.
American journal of hypertension.
32(7):668-675
[DOI] 10.1093/ajh/hpz022.
[PMID] 30753254.
2019
Subsequent Event Risk in Individuals With Established Coronary Heart Disease.
Circulation. Genomic and precision medicine.
12(4)
[DOI] 10.1161/CIRCGEN.119.002470.
[PMID] 30896328.
2019
β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies.
Journal of clinical pharmacology.
59(11):1462-1470
[DOI] 10.1002/jcph.1443.
[PMID] 31090079.
2018
2017 Is Banner Year for Drug Approvals by the Food and Drug Administration.
The American journal of medicine.
131(9):1025-1033
[DOI] 10.1016/j.amjmed.2018.02.034.
[PMID] 29626430.
2018
Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies.
BMC medical genomics.
11(1)
[DOI] 10.1186/s12920-018-0370-x.
[PMID] 29925376.
2018
Characterization of adult obesity in Florida using the OneFlorida clinical research consortium.
Obesity science & practice.
4(4):308-317
[DOI] 10.1002/osp4.274.
[PMID] 30151226.
2018
Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).
Circulation. Genomic and precision medicine.
11(4)
[DOI] 10.1161/CIRCGEN.117.001854.
[PMID] 29650764.
2018
Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients.
Journal of the American Heart Association.
7(6)
[DOI] 10.1161/JAHA.117.007339.
[PMID] 29523524.
2018
Genome-Wide Association Approach Identified Novel Genetic Predictors of Heart Rate Response to β-Blockers.
Journal of the American Heart Association.
7(5)
[DOI] 10.1161/JAHA.117.006463.
[PMID] 29478026.
2018
Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes.
The pharmacogenomics journal.
18(1):106-112
[DOI] 10.1038/tpj.2016.67.
[PMID] 27670767.
2018
Hypertension Across a Woman’s Life Cycle.
Journal of the American College of Cardiology.
71(16):1797-1813
[DOI] 10.1016/j.jacc.2018.02.033.
[PMID] 29673470.
2018
Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network.
Preventing chronic disease.
15
[DOI] 10.5888/pcd15.170332.
[PMID] 29494332.
2018
Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with high-normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database.
Journal of clinical hypertension (Greenwich, Conn.).
20(4):620-624
[DOI] 10.1111/jch.13247.
[PMID] 29532983.
2018
Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the INternational VErapamil-trandolapril STudy US cohort.
Journal of hypertension.
36(2):419-427
[DOI] 10.1097/HJH.0000000000001559.
[PMID] 28938338.
2018
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
JACC. Cardiovascular interventions.
11(2):181-191
[DOI] 10.1016/j.jcin.2017.07.022.
[PMID] 29102571.
2018
Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD.
The American journal of medicine.
131(12):1463-1472.e7
[DOI] 10.1016/j.amjmed.2018.08.005.
[PMID] 30142317.
2018
Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.
Pharmacogenetics and genomics.
28(11):251-255
[DOI] 10.1097/FPC.0000000000000353.
[PMID] 30289819.
2017
Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.
Journal of clinical hypertension (Greenwich, Conn.).
19(12):1301-1308
[DOI] 10.1111/jch.13094.
[PMID] 28940643.
2017
Branched-chain amino acid, meat intake and risk of type 2 diabetes in the Women’s Health Initiative.
The British journal of nutrition.
117(11):1523-1530
[DOI] 10.1017/S0007114517001568.
[PMID] 28721839.
2017
Challenges and strategies for implementing genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE (IGNITE) network.
BMC medical genomics.
10(1)
[DOI] 10.1186/s12920-017-0273-2.
[PMID] 28532511.
2017
Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.
Journal of clinical pharmacology.
57(3):305-311
[DOI] 10.1002/jcph.807.
[PMID] 27503364.
2017
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.
Journal of the American Heart Association.
6(11)
[DOI] 10.1161/JAHA.117.006522.
[PMID] 29097388.
2017
Genome-Wide and Gene-Based Meta-Analyses Identify Novel Loci Influencing Blood Pressure Response to Hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
69(1):51-59
[PMID] 27802415.
2017
Genome-Wide Prioritization and Transcriptomics Reveal Novel Signatures Associated With Thiazide Diuretics Blood Pressure Response.
Circulation. Cardiovascular genetics.
10(1)
[DOI] 10.1161/CIRCGENETICS.116.001404.
[PMID] 28115488.
2017
Genome-wide study of resistant hypertension identified from electronic health records.
PloS one.
12(2)
[DOI] 10.1371/journal.pone.0171745.
[PMID] 28222112.
2017
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.
The lancet. Diabetes & endocrinology.
5(7):534-543
[DOI] 10.1016/S2213-8587(17)30096-7.
[PMID] 28566218.
2017
Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics.
Journal of the American Heart Association.
7(1)
[DOI] 10.1161/JAHA.117.006656.
[PMID] 29288159.
2017
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
Clinical pharmacology and therapeutics.
102(3):502-510
[DOI] 10.1002/cpt.630.
[PMID] 28090649.
2017
Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics.
Scientific reports.
7(1)
[DOI] 10.1038/s41598-017-16343-z.
[PMID] 29167564.
2016
A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration.
Hypertension (Dallas, Tex. : 1979).
68(3):621-9
[DOI] 10.1161/HYPERTENSIONAHA.116.07328.
[PMID] 27381900.
2016
Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome.
Journal of women's health (2002).
25(9):875-81
[DOI] 10.1089/jwh.2015.5441.
[PMID] 27267867.
2016
CES1P1 variant -816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril.
European journal of clinical pharmacology.
72(6):681-7
[DOI] 10.1007/s00228-016-2029-x.
[PMID] 26915813.
2016
Comparison of Blood Pressure Control Rates Among Recommended Drug Selection Strategies for Initial Therapy of Hypertension.
American journal of hypertension.
29(10):1186-94
[DOI] 10.1093/ajh/hpw067.
[PMID] 27365079.
2016
Correction: Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy.
PloS one.
11(6)
[DOI] 10.1371/journal.pone.0157212.
[PMID] 27258057.
2016
Genetic loci associated with nonobstructive coronary artery disease in Caucasian women.
Physiological genomics.
48(1):12-20
[DOI] 10.1152/physiolgenomics.00067.2015.
[PMID] 26534935.
2016
Hypertension pharmacogenomics: in search of personalized treatment approaches.
Nature reviews. Nephrology.
12(2):110-22
[DOI] 10.1038/nrneph.2015.176.
[PMID] 26592190.
2016
Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.
Clinical and translational science.
9(1):36-42
[DOI] 10.1111/cts.12385.
[PMID] 26751406.
2016
Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease: Results From the US Cohort of the International Verapamil (SR)/Trandolapril Study.
Hypertension (Dallas, Tex. : 1979).
68(5):1110-1114
[PMID] 27620390.
2016
Melatonin Pathway and Atenolol-Related Glucose Dysregulation: Is There a Correlation?
Clinical and translational science.
9(2):114-22
[DOI] 10.1111/cts.12389.
[PMID] 26946962.
2016
Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women’s Heart Disease.
Journal of women's health (2002).
25(10):996-1003
[PMID] 27224417.
2016
Multiplex SNaPshot-a new simple and efficient CYP2D6 and ADRB1 genotyping method.
Human genomics.
10
[DOI] 10.1186/s40246-016-0073-3.
[PMID] 27108086.
2016
Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach.
Metabolomics : Official journal of the Metabolomic Society.
12(8)
[DOI] 10.1007/s11306-016-1076-8.
[PMID] 28217400.
2016
Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.
Hypertension (Dallas, Tex. : 1979).
67(3):556-63
[DOI] 10.1161/HYPERTENSIONAHA.115.06345.
[PMID] 26729753.
2016
Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol.
Metabolomics : Official journal of the Metabolomic Society.
12(10)
[DOI] 10.1007/s11306-016-1098-2.
[PMID] 28217401.
2015
Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients.
Metabolic syndrome and related disorders.
13(5):195-202
[DOI] 10.1089/met.2014.0132.
[PMID] 25664967.
2015
Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: an international verapamil SR-trandolapril ambulatory monitoring substudy.
PloS one.
10(4)
[DOI] 10.1371/journal.pone.0122726.
[PMID] 25835002.
2015
Genetics of resistant hypertension: a novel pharmacogenomics phenotype.
Current hypertension reports.
17(9)
[DOI] 10.1007/s11906-015-0583-8.
[PMID] 26198781.
2015
Home blood pressure monitoring with patient-initiated drug titration reduces blood pressure in high-risk patients with hypertension.
Evidence-based medicine.
20(2)
[DOI] 10.1136/ebmed-2014-110109.
[PMID] 25587130.
2015
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
The American journal of medicine.
128(2):137-43
[DOI] 10.1016/j.amjmed.2014.09.028.
[PMID] 25447610.
2015
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Journal of the American Heart Association.
4(1)
[DOI] 10.1161/JAHA.115.001778.
[PMID] 25622599.
2015
Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes.
CPT: pharmacometrics & systems pharmacology.
4(11):669-79
[DOI] 10.1002/psp4.12017.
[PMID] 26783503.
2015
PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.
Journal of hypertension.
33(11):2278-85
[DOI] 10.1097/HJH.0000000000000714.
[PMID] 26425837.
2015
Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease: the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation Study.
Cardiovascular endocrinology.
4(2):45-52
[PMID] 26665010.
2015
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.
Journal of hypertension.
33(6):1301-9
[DOI] 10.1097/HJH.0000000000000541.
[PMID] 25695618.
2015
Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorothiazide.
The pharmacogenomics journal.
15(2):153-7
[DOI] 10.1038/tpj.2014.46.
[PMID] 25201287.
2015
Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics.
Stem cells translational medicine.
4(12):1380-90
[DOI] 10.5966/sctm.2015-0126.
[PMID] 26494780.
2014
2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study.
Journal of the American College of Cardiology.
64(8):784-93
[DOI] 10.1016/j.jacc.2014.05.044.
[PMID] 25145522.
2014
Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women’s ischemia syndrome evaluation.
American heart journal.
167(6):826-32
[DOI] 10.1016/j.ahj.2014.01.017.
[PMID] 24890531.
2014
Alteration in fasting glucose after prolonged treatment with a thiazide diuretic.
Diabetes research and clinical practice.
104(3):363-9
[DOI] 10.1016/j.diabres.2014.04.004.
[PMID] 24794890.
2014
Association between high sensitivity C-reactive protein and metabolic syndrome in subjects completing the National Health and Nutrition Examination Survey (NHANES) 2009-10.
Diabetes & metabolic syndrome.
8(2):88-90
[DOI] 10.1016/j.dsx.2014.04.021.
[PMID] 24907172.
2014
Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE Study.
Journal of the American Heart Association.
3(1)
[DOI] 10.1161/JAHA.113.000660.
[PMID] 24584740.
2014
Clinical pharmacogenetics implementation: approaches, successes, and challenges.
American journal of medical genetics. Part C, Seminars in medical genetics.
166C(1):56-67
[DOI] 10.1002/ajmg.c.31390.
[PMID] 24616371.
2014
Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
Pharmacotherapy.
34(10):1102-12
[DOI] 10.1002/phar.1481.
[PMID] 25220280.
2014
Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations.
Human molecular genetics.
23(9):2498-510
[DOI] 10.1093/hmg/ddt626.
[PMID] 24345515.
2014
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci.
American journal of human genetics.
94(3):349-60
[DOI] 10.1016/j.ajhg.2013.12.016.
[PMID] 24560520.
2014
Genetics, ancestry, and hypertension: implications for targeted antihypertensive therapies.
Current hypertension reports.
16(8)
[DOI] 10.1007/s11906-014-0461-9.
[PMID] 24903233.
2014
Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African Americans.
The pharmacogenomics journal.
14(1):35-40
[DOI] 10.1038/tpj.2013.3.
[PMID] 23400010.
2014
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Journal of internal medicine.
276(5):486-97
[DOI] 10.1111/joim.12215.
[PMID] 24612202.
2014
Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate.
Clinical pharmacology and therapeutics.
96(2):175-81
[DOI] 10.1038/clpt.2014.62.
[PMID] 24637943.
2014
Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose?
Circulation. Cardiovascular genetics.
7(2):199-205
[DOI] 10.1161/CIRCGENETICS.113.000421.
[PMID] 24627569.
2014
Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension.
Journal of the American Heart Association.
3(6)
[DOI] 10.1161/JAHA.114.001398.
[PMID] 25385345.
2014
Misclassification in assessment of diabetogenic risk using electronic health records.
Pharmacoepidemiology and drug safety.
23(8):875-81
[DOI] 10.1002/pds.3656.
[PMID] 24923707.
2014
Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension.
American journal of hypertension.
27(4):546-54
[DOI] 10.1093/ajh/hpt124.
[PMID] 23886594.
2014
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension.
Journal of hypertension.
32(3):635-43
[DOI] 10.1097/HJH.0000000000000051.
[PMID] 24299915.
2014
Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Pharmacotherapy.
34(11):1132-40
[DOI] 10.1002/phar.1483.
[PMID] 25202885.
2014
PROX1 gene variant is associated with fasting glucose change after antihypertensive treatment.
Pharmacotherapy.
34(2):123-30
[DOI] 10.1002/phar.1355.
[PMID] 24122840.
2014
Reply to ‘Resistant hypertension revisited: definition and true prevalence’.
Journal of hypertension.
32(7)
[DOI] 10.1097/HJH.0000000000000220.
[PMID] 24984184.
2014
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Clinical pharmacology and therapeutics.
96(4):423-8
[DOI] 10.1038/clpt.2014.125.
[PMID] 24918167.
2014
Use of Medicare data to identify coronary heart disease outcomes in the Women’s Health Initiative.
Circulation. Cardiovascular quality and outcomes.
7(1):157-62
[DOI] 10.1161/CIRCOUTCOMES.113.000373.
[PMID] 24399330.
2013
Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression.
The pharmacogenomics journal.
13(3):257-63
[DOI] 10.1038/tpj.2012.4.
[PMID] 22350108.
2013
Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment.
The pharmacogenomics journal.
13(5):430-6
[DOI] 10.1038/tpj.2012.34.
[PMID] 22907731.
2013
Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.
Journal of hypertension.
31(4):698-704
[DOI] 10.1097/HJH.0b013e32835e2a71.
[PMID] 23353631.
2013
Atenolol induced HDL-C change in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076984.
[PMID] 24116192.
2013
Calcium antagonists in the treatment of coronary artery disease.
Current opinion in pharmacology.
13(2):301-8
[DOI] 10.1016/j.coph.2013.01.008.
[PMID] 23402734.
2013
Clinical utility of β-blockers for primary and secondary prevention of coronary artery disease.
Expert review of cardiovascular therapy.
11(3):289-91
[DOI] 10.1586/erc.13.16.
[PMID] 23469908.
2013
Generic drugs for hypertension: are they really equivalent?
Current hypertension reports.
15(4):340-5
[DOI] 10.1007/s11906-013-0353-4.
[PMID] 23700299.
2013
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide.
Hypertension (Dallas, Tex. : 1979).
62(2):391-7
[DOI] 10.1161/HYPERTENSIONAHA.111.00436.
[PMID] 23753411.
2013
Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes.
Pharmacogenetics and genomics.
23(12):697-705
[DOI] 10.1097/FPC.0000000000000012.
[PMID] 24128935.
2013
Influence of Tyrphostin AG490 on the expression of diabetes-associated markers in human adipocytes.
Immunogenetics.
65(1):83-90
[DOI] 10.1007/s00251-012-0659-4.
[PMID] 23081744.
2013
Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort.
Journal of translational medicine.
11
[DOI] 10.1186/1479-5876-11-12.
[PMID] 23302499.
2013
Loci influencing blood pressure identified using a cardiovascular gene-centric array.
Human molecular genetics.
22(8):1663-78
[DOI] 10.1093/hmg/dds555.
[PMID] 23303523.
2013
Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).
Clinical cardiology.
36(8):442-7
[DOI] 10.1002/clc.22145.
[PMID] 23720247.
2013
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes.
Hypertension (Dallas, Tex. : 1979).
62(1):48-54
[DOI] 10.1161/HYPERTENSIONAHA.111.00823.
[PMID] 23690342.
2013
Pharmacometabolomics reveals racial differences in response to atenolol treatment.
PloS one.
8(3)
[DOI] 10.1371/journal.pone.0057639.
[PMID] 23536766.
2013
Simple integer risk score to determine prognosis of patients with hypertension and chronic stable coronary artery disease.
Journal of the American Heart Association.
2(4)
[DOI] 10.1161/JAHA.113.000205.
[PMID] 23948642.
2013
The next 10 years in antihypertensive treatment. Interview by Tanya Stezhka.
Expert review of cardiovascular therapy.
11(6):669-71
[DOI] 10.1586/erc.13.57.
[PMID] 23750675.
2012
Alpha Adducin-1 (Add1)Singlenucleotide Polymorphism (Snp) Associated With New Onset Diabetes Risk With Hydrochlorothiazide (Hctz) Therapy in the International Verapamil Sr Trandolapril Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91
2012
Antihypertensive Medication Exposure and Adverse Glycemic Effects: An Evaluation of Fasting and Stimulated Glucose
Clinical Pharmacology & Therapeutics.
91
2012
Association of Fto With Hydrochlorothiazide (Hctz)-Induced Elevation in Uric Acid (Ua) in African American (Aa) Hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (Pear) Study.
Clinical Pharmacology & Therapeutics.
91:S59-S60
2012
Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol.
American journal of hypertension.
25(3):359-65
[DOI] 10.1038/ajh.2011.215.
[PMID] 22089105.
2012
Clinical Predictors of Dysglycemic Effects Associated With Use of Beta Blockers and Thiazide Diuretics
Clinical Pharmacology & Therapeutics.
91:S24-S25
2012
Comparing marginal structural models to standard methods for estimating treatment effects of antihypertensive combination therapy.
BMC medical research methodology.
12
[DOI] 10.1186/1471-2288-12-119.
[PMID] 22866767.
2012
Correspondence regarding “Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats”.
Biochemical pharmacology.
83(6)
[DOI] 10.1016/j.bcp.2011.12.033.
[PMID] 22227275.
2012
Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-56.
[PMID] 22440088.
2012
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension.
Hypertension (Dallas, Tex. : 1979).
60(4):957-64
[DOI] 10.1161/HYPERTENSIONAHA.112.198721.
[PMID] 22949529.
2012
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study.
Circulation. Cardiovascular genetics.
5(6):686-91
[DOI] 10.1161/CIRCGENETICS.112.964080.
[PMID] 23087401.
2012
Hypertension Susceptibility Loci Associated With Blood Pressure Response To Antihypertensives- Results From the Pharmacogenomic Evaluation of Antihypertensive Responses (Pear) Study.
Clinical Pharmacology & Therapeutics.
91
2012
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci.
American journal of human genetics.
91(5):823-38
[DOI] 10.1016/j.ajhg.2012.08.032.
[PMID] 23063622.
2012
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci.
American journal of human genetics.
90(3):410-25
[DOI] 10.1016/j.ajhg.2011.12.022.
[PMID] 22325160.
2012
Mortality Associated With Angina and Blood Pressure Control Among Hypertensive Patients With Coronary Artery Disease: New Data From Extended Follow-Up of the International Verapamil/Trandolapril Study
Journal of the American College of Cardiology.
59
2012
Mortality Associated With Angina and Blood Pressure Control Among Hypertensive Patients With Coronary Artery Disease: New Data From Extended Follow-Up of the International Verapamil/Trandolapril Study
Journal of the American College of Cardiology.
59
2012
Non-Synonymous Snps in Sele, Selp, and Siglec12 Associate With Cardiovascular (Cv) Outcomes in the International Verapamil Sr-Trandol-April Study Genetic Substudy (Invest-Genes)
Clinical Pharmacology & Therapeutics.
91:S20-S21
2012
Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response.
Journal of translational medicine.
10
[DOI] 10.1186/1479-5876-10-47.
[PMID] 22413836.
2012
Relationships Between Components of Metabolic Syndrome and Coronary Intravascular Ultrasound (Ivus) Atherosclerosis Measures in Women Without Obstructive Coronary Artery Disease: the Nhlbi-Sponsored Women’S Ischemia Syndrome Evaluation (Wise) Study
Journal of the American College of Cardiology.
59(13, S)
2012
Simple Prediction of Long-Term Mortality Among Hypertensive Patients With Coronary Artery Disease: New Data From An Extended Follow-Up of the International Verapamil-Sr/Trandolapril Study (Invest)
Journal of the American College of Cardiology.
59
2012
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Clinical pharmacology and therapeutics.
92(1):112-7
[DOI] 10.1038/clpt.2012.57.
[PMID] 22617227.
2012
The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice.
PloS one.
7(5)
[DOI] 10.1371/journal.pone.0036079.
[PMID] 22615750.
2012
Treatment-Resistant Blood Pressure Among Patients With Coronary Artery Disease – Cause for Concern: New Data From the Extended Follow-Up of the International Verapamail Sr-Trandolapril Study (Invest)
Journal of the American College of Cardiology.
59
2012
Trends in Utilization of Medications With Adverse Metabolic Effects in a Managed Care Population Between 1999 and 2008
Pharmacoepidemiology and Drug Safety.
21
2011
Blood pressure lowering in patients with diabetes–one level might not fit all.
Nature reviews. Cardiology.
8(1):42-9
[DOI] 10.1038/nrcardio.2010.182.
[PMID] 21079637.
2011
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease.
Circulation. Cardiovascular genetics.
4(2):169-78
[DOI] 10.1161/CIRCGENETICS.110.959296.
[PMID] 21372283.
2011
Does Angiotensin Plus Aldosterone Inhibition Improve Coronary Endothelial Function? An Ancillary Study From the Nhlbi-Sponsored Women’s Ischemia Syndrome Evaluation (Wise)
Journal of the American College of Cardiology.
57
2011
Effect of phosphodiesterase type 5 inhibition on microvascular coronary dysfunction in women: a Women’s Ischemia Syndrome Evaluation (WISE) ancillary study.
Clinical cardiology.
34(8):483-7
[DOI] 10.1002/clc.20935.
[PMID] 21780138.
2011
Genetic Variation in the Calcium Signaling Pathway and Association With Outcomes in Hypertensive Coronary Artery Disease Patients
Clinical Pharmacology & Therapeutics.
89
2011
Genetic Variation in the Calcium Signaling Pathway and Association With Outcomes in Hypertensive Coronary Artery Disease Patients
Clinical Pharmacology & Therapeutics.
89
2011
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
The American journal of medicine.
124(7):614-20
[DOI] 10.1016/j.amjmed.2011.02.025.
[PMID] 21596367.
2011
In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE).
American heart journal.
162(4):678-84
[DOI] 10.1016/j.ahj.2011.07.011.
[PMID] 21982660.
2011
Influence of G Protein Receptor Kinase 4 (Grk4) Polymorphisms On Blood Pressure Response To the Beta-Blocker Atenolol.
Clinical Pharmacology & Therapeutics.
89
2011
Kcnj1 Snps Are Associated With Increased Fasting Glucose and Risk of New Onset Diabetes During Hctz Therapy
Clinical Pharmacology & Therapeutics.
89
2011
Liver X receptor α gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study.
Pharmacogenetics and genomics.
21(6):333-40
[DOI] 10.1097/FPC.0b013e3283452fec.
[PMID] 21562465.
2011
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients.
Pharmacogenetics and genomics.
21(1):42-9
[DOI] 10.1097/FPC.0b013e328341e911.
[PMID] 21127457.
2011
Response To Letter Regarding Article “Chromosome 9P21 Haplotypes and Prognosis in White and Black Patients With Coronary Artery Disease”
Circulation-Cardiovascular Genetics.
4(4)
[DOI] 10.1161/CIRCGENETICS.111.960807.
2010
A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE).
American heart journal.
159(6):987.e1-7
[DOI] 10.1016/j.ahj.2010.03.024.
[PMID] 20569710.
2010
Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner.
PloS one.
5(12)
[DOI] 10.1371/journal.pone.0015180.
[PMID] 21170323.
2010
Association Between Melatonin Receptor 1B Single Nucleotide Polymorphisms (Snps) and Response To Antihypertensive Drugs.
Clinical Pharmacology & Therapeutics.
87
2010
Atenolol exposure and risk for development of adverse metabolic effects: a pilot study.
Pharmacotherapy.
30(9):872-8
[DOI] 10.1592/phco.30.9.872.
[PMID] 20795842.
2010
Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST substudy.
The American journal of medicine.
123(8):719-26
[DOI] 10.1016/j.amjmed.2010.02.014.
[PMID] 20670726.
2010
Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage- Gated Calcium Channel ( Cacnb2) With Outcomes in Hypertensive Coronary Artery Disease ( Cad) Patients.
Clinical Pharmacology & Therapeutics.
87
2010
Clinical Association of Variation in the Beta 2 Regulatory Subunit of the Voltage- Gated Calcium Channel (Cacnb2) With Outcomes in Hypertensive Coronary Artery Disease (Cad) Patients.
Clinical Pharmacology & Therapeutics.
87
2010
Coronary revascularization strategy and outcomes according to blood pressure (from the International Verapamil SR-Trandolapril Study [INVEST]).
The American journal of cardiology.
106(4):498-503
[DOI] 10.1016/j.amjcard.2010.03.056.
[PMID] 20691307.
2010
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES).
Circulation. Cardiovascular genetics.
3(6):548-55
[DOI] 10.1161/CIRCGENETICS.110.957654.
[PMID] 21156931.
2010
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Hypertension (Dallas, Tex. : 1979).
55(1):61-8
[DOI] 10.1161/HYPERTENSIONAHA.109.139592.
[PMID] 19917874.
2010
Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics.
Expert review of cardiovascular therapy.
8(6):793-802
[DOI] 10.1586/erc.10.27.
[PMID] 20528637.
2010
New-Onset Diabetes Risk Associated With Antihypertensive Therapy in Hypertensive Coronary Artery Disease Patients Is Modified By a Single Nucleotide Polymorphism (Snp) in the L-Type Calcium Channel (Ltcc)
Clinical Pharmacology & Therapeutics.
87
2010
Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy.
Hypertension (Dallas, Tex. : 1979).
55(1):48-53
[DOI] 10.1161/HYPERTENSIONAHA.109.142240.
[PMID] 19996066.
2010
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.
American journal of hypertension.
23(9):1014-22
[DOI] 10.1038/ajh.2010.98.
[PMID] 20725057.
2010
The use of diuretics plus calcium channel blockers for hypertension may be associated with a higher risk of myocardial infarction but not stroke compared with the combination of diuretics plus beta blockers.
Evidence-based medicine.
15(3):92-3
[DOI] 10.1136/ebm1067.
[PMID] 20522694.
2010
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.
JAMA.
304(1):61-8
[DOI] 10.1001/jama.2010.884.
[PMID] 20606150.
2009
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project.
Archives of internal medicine.
169(9):843-50
[DOI] 10.1001/archinternmed.2009.50.
[PMID] 19433695.
2009
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.
Expert review of cardiovascular therapy.
7(6):689-702
[DOI] 10.1586/erc.09.31.
[PMID] 19505284.
2009
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response.
Circulation. Cardiovascular genetics.
2(4):362-70
[DOI] 10.1161/CIRCGENETICS.109.857839.
[PMID] 20031608.
2009
Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Journal of the American College of Cardiology.
53(5 Suppl):S28-34
[DOI] 10.1016/j.jacc.2008.10.037.
[PMID] 19179214.
2009
Characteristics and outcomes of revascularized patients with hypertension: an international verapamil SR-trandolapril substudy.
Hypertension (Dallas, Tex. : 1979).
53(4):624-30
[DOI] 10.1161/HYPERTENSIONAHA.108.111542.
[PMID] 19237684.
2009
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension.
American journal of hypertension.
22(7):748-53
[DOI] 10.1038/ajh.2009.81.
[PMID] 19407804.
2009
Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order.
Clinical pharmacology and therapeutics.
86(5):533-9
[DOI] 10.1038/clpt.2009.101.
[PMID] 19571804.
2009
Importance of Blood Pressure Control in Hypertensive Patients With Coronary Heart Disease in Clinical Practice To Reduce the Risk of Stroke Response
Stroke.
40(6)
[DOI] 10.1161/STROKEAHA.108.521575.
2009
Incident Or Continued Angina During Hypertension Treatment Is Associated With Increased Risk of Death, Mi, Or Stroke Among Patients With Known Cad: a Substudy of the International Verapamil/Trandolapril Study (Invest)
Circulation.
120:S440-S441
2009
INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.
Expert review of cardiovascular therapy.
7(11):1329-40
[DOI] 10.1586/erc.09.102.
[PMID] 19900016.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study
Pharmacotherapy.
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Lack of correlation between thiazide-induced hyperglycemia and hypokalemia: subgroup analysis of results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study.
Pharmacotherapy.
29(10):1157-65
[DOI] 10.1592/phco.29.10.1157.
[PMID] 19792989.
2009
Long-Term Mortality Associated With New Onset Diabetes in Hypertensive Cad Patients Following Exposure To Antihypertensive Medications: Findings From the International Verapamail Sr-Trandolapril Study (Invest)
Journal of the American College of Cardiology.
53
2009
Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.
American heart journal.
157(3):442-9
[DOI] 10.1016/j.ahj.2008.11.018.
[PMID] 19249413.
2009
Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension.
Clinical pharmacology and therapeutics.
85(1):36-44
[DOI] 10.1038/clpt.2008.194.
[PMID] 18946466.
2009
Systolic blood pressure and subjective well-being in patients with coronary artery disease.
Clinical cardiology.
32(11):627-32
[DOI] 10.1002/clc.20501.
[PMID] 19711440.
2008
Adrenergic gene polymorphisms and cardiovascular risk in the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation.
Journal of translational medicine.
6
[DOI] 10.1186/1479-5876-6-11.
[PMID] 18331634.
2008
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES).
American heart journal.
156(2):397-404
[DOI] 10.1016/j.ahj.2008.03.007.
[PMID] 18657677.
2008
beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension.
Clinical pharmacology and therapeutics.
84(6):715-21
[DOI] 10.1038/clpt.2008.139.
[PMID] 18615004.
2008
Cacnaic Polymorphisms and Cardiovascular Outcomes in the International Verapamil Sr/Trandolapril Study-Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Diabetes Risk Associated With Beta 1-Adrenergic Receptor Polymorphisms Differs By Antihypertensive Drug Therapy: Results From the International Verapamil Sr/Trandolapril Study – Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Dysglycemia During Treatment With Hctz in Patients With Hypertension and Metabolic Syndrome
Circulation.
118
2008
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST).
European heart journal.
29(10):1327-34
[DOI] 10.1093/eurheartj/ehn123.
[PMID] 18375982.
2008
Liver X Receptor-Alpha Gene Variability and Cardiovascular Risk in the International Verapamil Sr/Trandolapril Study – Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Madd Variants and Risk of Cardiovascular Events in the International Verapamil Sr/Trandolapril Study – Genetic Substudy (Invest Genes).
Clinical Pharmacology & Therapeutics.
83:S82-S83
2008
Madd Variants and Risk of Cardiovascular Events in the International Verapamil Sr/Trandolapril Study – Genetic Substudy (Invest Genes).
Clinical Pharmacology & Therapeutics.
83:S82-S83
2008
Nos3 Polymorphisms Do Not Associate With Adverse Clinical Outcomes in Elderly Hypertensives With Coronaryartery Disease: Analysis of the International Verapamil Sr-Trandolapril Study Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Nos3 Polymorphisms Do Not Associate With Adverse Clinical Outcomes in Elderly Hypertensives With Coronaryartery Disease: Analysis of the International Verapamil Sr-Trandolapril Study Genetic Substudy (Invest-Genes).
Clinical Pharmacology & Therapeutics.
83
2008
Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation.
The Journal of clinical endocrinology and metabolism.
93(4):1276-84
[DOI] 10.1210/jc.2007-0425.
[PMID] 18182456.
2008
Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST.
Stroke.
39(2):343-8
[PMID] 18162623.
2008
Thiazide-induced dysglycemia: it’s time to take notice.
Expert review of cardiovascular therapy.
6(10):1291-4
[DOI] 10.1586/14779072.6.10.1291.
[PMID] 19018679.
2007
Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.
Clinical pharmacology and therapeutics.
81(3):386-91
[PMID] 17339868.
2007
Dual therapy in hypertensive patients with coronary artery disease: the role of calcium channel blockers and beta-blockers.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
7 Suppl 1:25-9
[PMID] 19845074.
2007
Effect of ramipril on the incidence of diabetes.
The New England journal of medicine.
356(5):523; author reply 523-4
[PMID] 17269176.
2007
Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).
The American journal of cardiology.
99(11):1549-54
[PMID] 17531579.
2007
Influence of Hispanic ethnicity on blood pressure control and cardiovascular outcomes in women with CAD and hypertension: findings from INVEST.
Journal of women's health (2002).
16(5):632-40
[PMID] 17627399.
2007
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST).
Pharmacogenetics and genomics.
17(9):719-29
[PMID] 17700361.
2007
Metabolic syndrome and cardiovascular disease: challenges and opportunities.
Clinical cardiology.
30(12):593-7
[PMID] 17607758.
2007
Obesity paradox in patients with hypertension and coronary artery disease.
The American journal of medicine.
120(10):863-70
[PMID] 17904457.
2006
Blood pressure control and cardiovascular outcomes in high-risk Hispanic patients–findings from the International Verapamil SR/Trandolapril Study (INVEST).
American heart journal.
151(5):1072-9
[PMID] 16644338.
2006
Predictors of adverse outcome among patients with hypertension and coronary artery disease.
Journal of the American College of Cardiology.
47(3):547-51
[PMID] 16458134.
2006
Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]).
The American journal of cardiology.
98(7):890-4
[PMID] 16996868.
2006
Ranolazine is associated with cardiovascular and metabolic improvement: a win-win for patients with diabetes.
European heart journal.
27(1):5-6
[PMID] 16267073.
2005
A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.
Journal of clinical hypertension (Greenwich, Conn.).
7(11):654-63
[PMID] 16278523.
2005
Global differences in blood pressure control and clinical outcomes in the INternational VErapamil SR-Trandolapril STudy (INVEST).
Clinical cardiology.
28(7):321-8
[PMID] 16075824.
2004
Cardiovascular therapies and risk for development of diabetes.
Journal of the American College of Cardiology.
44(3):509-12
[PMID] 15358012.
2004
Characteristics of contemporary patients with hypertension and coronary artery disease.
Clinical cardiology.
27(10):571-6
[PMID] 15553310.
2004
Clinical outcomes in the diabetes cohort of the INternational VErapamil SR-Trandolapril study.
Hypertension (Dallas, Tex. : 1979).
44(5):637-42
[PMID] 15381674.
2003
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
JAMA.
290(21):2805-16
[PMID] 14657064.
2003
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
The American journal of cardiology.
91(3):274-9
[PMID] 12565082.
2001
Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial.
Clinical cardiology.
24(11 Suppl):V14-6
[PMID] 11712771.
2001
How will INVEST and other hypertension trials change clinical practice?
Clinical cardiology.
24(11 Suppl):V24-9
[PMID] 11712773.
2000
The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study.
Diabetes care.
23(4):504-9
[PMID] 10857943.
1998
Rationale and Design of the International Verapamil SR/Trandolapril Study (INVEST): An Internet-Based Randomized Trial in Coronary Artery Disease Patients with Hypertension
Journal of the American College of Cardiology.
(32(5)):1228-1237
1998
Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension.
Journal of the American College of Cardiology.
32(5):1228-37
[PMID] 9809930.
Grants
Jun 2022
ACTIVE
Genetic Associations of Ischemic Heart Disease and Symptoms Among Diverse Postmenopausal Women
Role: Co-Investigator
Funding: NATL INST OF HLTH NIA
Apr 2020
– Mar 2021
Use of Real-World Evidence to Characterize Patients with Uncontrolled Hypertension
Role: Co-Investigator
Funding: YALE CENTER FOR OUTCOMES RESEARCH & EVAL
via MEDICAL DEVICE INNOVATION CONSORTIUM
May 2019
– Jul 2021
Research Collaboration Agreement for Data Transfer and Use of Limited Data Set
Role: Principal Investigator
Funding: DUKE UNIVERSITY
via PATIENT-CENTERED OUTCOMES RES INST
Nov 2018
– Nov 2019
Cardiovascular Health Collaborative Research Group
Role: Principal Investigator
Funding: PATIENT-CENTERED OUTCOMES RES INST
Sep 2018
– Jun 2023
Using PCORnet to Compare Blood Pressure Control Strategies
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via PATIENT-CENTERED OUTCOMES RES INST
Jul 2018
– Jun 2023
Advancing Personalized Hypertension Care through Big Data Science
Role: Other
Funding: NATL INST OF HLTH NHLBI
Jun 2018
– Jun 2022
INTEGRATIVE DATA APPROCACHES FOR RESISTANT HYPERTENSION IDENTIFICATION AND PREDICTION
Role: Other
Funding: NATL INST OF HLTH NHLBI
Jan 2017
– Aug 2018
PCORnet Cardiovascular Health Collaborative Research Group
Role: Principal Investigator
Funding: UNIV OF CALIFORNIA SAN FRANCISCO
via PATIENT-CENTERED OUTCOMES RES INST
Oct 2015
– Mar 2019
OneFlorida Clinical Research Consortium Phase II
Role: Project Manager
Funding: PATIENT-CENTERED OUTCOMES RES INST
May 2015
– Apr 2016
Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
Role: Principal Investigator
Funding: FL HLTH EQUITY RESEARCH INST
Apr 2015
– Jun 2021
Clinical and Translational Science Institute (CTSI)
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Aug 2010
– Jul 2017
Pharmacogenomic Evaluation of Antihypertensive Responses.
Role: Co-Investigator
Funding: NATL INST OF HLTH NIGMS
Jul 2007
– Aug 2016
Clinical and Translational Science Institute
Role: Project Manager
Funding: UF RESEARCH FOU
Education
M.S.
2007
·
University of Florida
Pharm.D.
1986
·
University of California at San Fransisco
Contact Details
Phones:
- Business:
- (352) 359-2658
Emails:
- Business:
- rmdehoff@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 115500
GAINESVILLE FL 32611 - Business Street:
-
1600 SW ARCHER RD
MSB PG-05A
GAINESVILLE FL 326103003